J.A. Lieberman

Medicine · Health Sciences

22h-index3.1kcitations96works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Schizophrenia research and treatment(53), Functional Brain Connectivity Studies(14), Bipolar Disorder and Treatment(11), Treatment of Major Depression(11), Mental Health and Psychiatry(9)

Publications96 total

Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection
UNC Libraries·2020Open Access
Regional Gray Matter Growth, Sexual Dimorphism, and Cerebral Asymmetry in the Neonatal Brain
UNC Libraries·2020· 12 citedOpen Access
Chapter 2. Natural History
American Psychiatric Association Publishing eBooks·2020
Erratum: Genomewide association for schizophrenia in the CATIE study: results of stage 1
Molecular Psychiatry·2009· 23 citedOpen Access
Antipsychotic drugs: Comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection (Pharmacological Reviews (2002) 60, (358-403))
Pharmacological Reviews·2008· 19 cited
PHARMACOGENETICS OF SCHIZOPHRENIA: TARDIVE DYSKINESIA AND WEIGHT GAIN
Schizophrenia Research·2008
Aggression and Quantitative MRI Measures of Caudate in Patients With Chronic Schizophrenia or Schizoaffective Disorder
Journal of Neuropsychiatry·2006· 45 citedOpen Access
0394 CLINICAL EFFECTIVENESS AND PREDICTORS OF TREATMENT NON-ADHERENCE: COMPARISON OF OLANZAPINE, QUETIAPINE, AND RISPERIDONE IN FIRST-EPISODE PSYCHOSIS
Schizophrenia Research·2006· 7 cited
TC18C MRI OF BRAIN VOLUMES AT THE PRODROME AND FIRST EPISODE STAGES OF SCHIZOPHRENIA
Schizophrenia Research·2006
P.3.a.047 Remission in schizophrenia: a comparison of 2 dose regimens of ziprasidone versus haloperidol in a 40-week core and 3-year double-blind continuation study
European Neuropsychopharmacology·2006
P.3.c.054 Olanzapine, quetiapine, and risperidone in the treatment of first-episode psychosis: effectiveness and factors influencing adherence to treatment
European Neuropsychopharmacology·2006· 4 cited
P.2.131 Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia
European Neuropsychopharmacology·2003· 1 cited
P.2.085 Amphetamine and stress-induced behaviors and c-Fos expression in a genetic model of NMDA receptor hypofunction
European Neuropsychopharmacology·2003
S.14.05 Long-term efficacy and safety of atypical and conventional antipsychotic drugs in first episode schizophrenia
European Neuropsychopharmacology·2003· 3 cited
No association between the COMT VAL158MET polymorphism and antipsychotic response in schizophrenia
Schizophrenia Research·2003
Olanzapine induced reductions in frontal lobe lactate levels correlate with treatment response in first episode psychosis
Schizophrenia Research·2003· 4 cited
Functional MRI assessment of atypical and conventional antipsychotic effects on cognitive function in schizophrenia patients
Schizophrenia Research·2003
Comparison of behavioral effects of olanzapine and clozapine in a genetic model of NMDA receptor hypofunction
Schizophrenia Research·2003
Cortical-subcortical dysconnectivity expressed by attenuated cortical c-fos induction by acute amphetamine treatment or acute swim stress in mice with reduced NMDA receptor1 expression
Schizophrenia Research·2003
Neurocognitive effects of olanzapine and low-dose haloperidol: A two-year treatment study in first episode psychosis
Schizophrenia Research·2003· 4 cited
page 1 of 5Next →

Frequent Co-authors

S. Szymanski(11), John M. Kane(11), Miranda Chakos(9), Diana O. Perkins(7), Robert M. Bilder(6), Michael Borenstein(6), Simcha Pollack(6), Robert M. Hamer(6), José Alvir(5), Margaret G. Woerner(5), Allan Z. Safferman(4), Michael H. Kronig(4), David Mayerhoff(4), A. Koreen(4), José Alvir(4), Brian Sheitman(4), S. Geisler(4), J. McEvoy(4), T. Sharma(4), M. Tohen(4)